COT.V - Cotinga Pharmaceuticals Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.0650
0.0000 (0.00%)
At close: 2:03PM EDT
Stock chart is not supported by your current browser
Previous Close0.0650
Open0.0650
Bid0.0450 x 0
Ask0.0600 x 0
Day's Range0.0650 - 0.0650
52 Week Range0.0200 - 0.3700
Volume17,000
Avg. Volume9,938
Market Cap1.429M
Beta (5Y Monthly)5.37
PE Ratio (TTM)N/A
EPS (TTM)-0.1040
Earnings DateApr. 04, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
  • CNW Group

    IIROC Trading Resumption - COT

    VANCOUVER , Nov. 7, 2019 /CNW/ - Trading resumes in: Company: Cotinga Pharmaceuticals Inc TSX-Venture Symbol: COT (all issues) Resumption (ET): 9:30 AM  November 8, 2019 IIROC can make a decision to impose ...

  • CNW Group

    IIROC Trading Halt - COT

    VANCOUVER , Oct. 7, 2019 /CNW/ - The following issues have been halted by IIROC: Company: Cotinga Pharmaceuticals Inc TSX-Venture Symbol: COT (All Issues) Reason: Cease Trade Order Halt Time (ET): 8:00 ...

  • GlobeNewswire

    Cotinga Pharmaceuticals Releases Additional Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has released additional interim data of its ongoing Phase 1b/2a clinical trial of COTI-2 plus cisplatin in solid tumors. “We are pleased to continue updating our investment community as we progress the combination trial evaluating COTI-2 plus cisplatin in solid tumors,” said Alison Silva, Cotinga’s President & CEO.

  • GlobeNewswire

    Cotinga Pharmaceuticals Announces Initiation of Next Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has initiated the third cohort of its ongoing Phase 1b/2a clinical trial of COTI-2 plus cisplatin in solid tumors. The objective of the third cohort is to continue to evaluate the safety and tolerability of COTI-2 in combination with standard-of-care cisplatin.

  • GlobeNewswire

    Cotinga Pharmacueticals Announces Closing of Second Tranche of Unit Offering

    Cotinga Pharmaceuticals  Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that effective June 4, 2019 (the “Closing Date”), it completed, for gross proceeds of $100,000, a second tranche offering (the “Offering”) of units (“Units”) comprised of $100,000 of senior secured debentures (the “Debentures”) and 1,000,000 non-transferable common share purchase warrants exercisable at $0.10 per Warrant to arm’s length lenders and a lender who is a director and officer of the Company (the “Subscribers”). The Company intends to use the proceeds from the Offering to fund the initiation of both COTI-2 combination trials (one in solid tumors with cisplatin and the other in triple negative breast cancer with eribulin) and for general operations as well as corporate purposes.

  • GlobeNewswire

    Cotinga Pharmacueticals Announces Closing of Unit Offering

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that effective May 22, 2019 (the “Closing Date”), it completed, for gross proceeds of $199,970, an offering (the “Offering”) of units (“Units”) comprised of $199,970 of senior secured debentures (the “Debentures”) and 1,999,700 non-transferable common share purchase warrants exercisable at $0.10 per Warrant to arm’s length lenders and a lender who is a director of the Company (the “Subscribers”). The Company intends to use the proceeds from the Offering to fund the initiation of both COTI-2 combination trials (one in solid tumors with cisplatin and the other in triple negative breast cancer with eribulin) and for general operations as well as corporate purposes.

  • GlobeNewswire

    Cotinga Pharmaceuticals Releases Early Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors

    Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has released early interim data of its ongoing Phase 1b/2a clinical trial of COTI-2 plus cisplatin in solid tumors. The primary objective of the second cohort is to continue to evaluate the safety and tolerability of COTI-2 in combination with standard-of-care cisplatin.  Secondary objectives include determination of efficacy and pharmacokinetics profiling.

  • GlobeNewswire

    Cotinga Pharmaceuticals Reports Fiscal 2019 Third Quarter Financial and Operating Results

    OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and operating results today for the three and nine months ended January 31, 2019. The Company announced that it has entered into a research partnership with St. Vincent’s University Hospital in Dublin, Ireland with the intent to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer (TNBC).